What one share of MBX Biosciences holds
We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development.
MBX Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.41 |
|---|---|
| Capex (buildings and equipment) | $0.06 |
| Free cash flow | −$1.97 |
| Cash and investments | $8.73 |
| Book value | $8.54 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$31.96 | $0.13 | −$31.52 | — | −$57.65 |
| 2024 | — | −$5.82 | $0.08 | −$5.22 | — | — |
| 2025 | — | −$2.38 | $0.05 | −$2.24 | — | $8.22 |
Common questions about MBX Biosciences
How much does one share of MBX Biosciences earn?
Over the last 12 months, MBX Biosciences lost $2.41 for each share.
Does MBX Biosciences pay a dividend?
MBX Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is MBX Biosciences’s book value per share?
MBX Biosciences’s book value is $8.54 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of MBX Biosciences have?
Each share of MBX Biosciences has $8.73 of cash and investments, as of June 30, 2026.
What is MBX Biosciences’s free cash flow per share?
−$1.97 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.